Veterans Affairs Kept COVID-19 Vaccine Mandate in Place Without Evidence

The U.S. Department of Veterans Affairs (VA) reviewed no data when deciding in 2023 to keep its COVID-19 vaccine mandate in place.

VA Secretary Denis McDonough said on May 1, 2023, that the end of many other federal mandates “will not impact current policies at the Department of Veterans Affairs.”

He said the mandate was remaining for VA health care personnel “to ensure the safety of veterans and our colleagues.”

Mr. McDonough did not cite any studies or other data. A VA spokesperson declined to provide any data that was reviewed when deciding not to rescind the mandate. The Epoch Times submitted a Freedom of Information Act for “all documents outlining which data was relied upon when establishing the mandate when deciding to keep the mandate in place.”

The agency searched for such data and did not find any.

“The VA does not even attempt to justify its policies with science, because it can’t,” Leslie Manookian, president and founder of the Health Freedom Defense Fund, told The Epoch Times.

“The VA just trusts that the process and cost of challenging its unfounded policies is so onerous, most people are dissuaded from even trying,” she added.

The VA’s mandate remains in place to this day.

The VA’s website claims that vaccines “help protect you from getting severe illness” and “offer good protection against most COVID-19 variants,” pointing in part to observational data from the U.S. Centers for Disease Control and Prevention (CDC) that estimate the vaccines provide poor protection against symptomatic infection and transient shielding against hospitalization.

There have also been increasing concerns among outside scientists about confirmed side effects like heart inflammation—the VA hid a safety signal it detected for the inflammation—and possible side effects such as tinnitus, which shift the benefit-risk calculus.

President Joe Biden imposed a slate of COVID-19 vaccine mandates in 2021. The VA was the first federal agency to implement a mandate.

President Biden rescinded the mandates in May 2023, citing a drop in COVID-19 cases and hospitalizations. His administration maintains the choice to require vaccines was the right one and saved lives.

“Our administration’s vaccination requirements helped ensure the safety of workers in critical workforces including those in the healthcare and education sectors, protecting themselves and the populations they serve, and strengthening their ability to provide services without disruptions to operations,” the White House said.

Some experts said requiring vaccination meant many younger people were forced to get a vaccine despite the risks potentially outweighing the benefits, leaving fewer doses for older adults.

“By mandating the vaccines to younger people and those with natural immunity from having had COVID, older people in the U.S. and other countries did not have access to them, and many people might have died because of that,” Martin Kulldorff, a professor of medicine on leave from Harvard Medical School, told The Epoch Times previously.

The VA was one of just a handful of agencies to keep its mandate in place following the removal of many federal mandates.

“At this time, the vaccine requirement will remain in effect for VA health care personnel, including VA psychologists, pharmacists, social workers, nursing assistants, physical therapists, respiratory therapists, peer specialists, medical support assistants, engineers, housekeepers, and other clinical, administrative, and infrastructure support employees,” Mr. McDonough wrote to VA employees at the time.

“This also includes VA volunteers and contractors. Effectively, this means that any Veterans Health Administration (VHA) employee, volunteer, or contractor who works in VHA facilities, visits VHA facilities, or provides direct care to those we serve will still be subject to the vaccine requirement at this time,” he said. “We continue to monitor and discuss this requirement, and we will provide more information about the vaccination requirements for VA health care employees soon. As always, we will process requests for vaccination exceptions in accordance with applicable laws, regulations, and policies.”

The version of the shots cleared in the fall of 2022, and available through the fall of 2023, did not have any clinical trial data supporting them.

A new version was approved in the fall of 2023 because there were indications that the shots not only offered temporary protection but also that the level of protection was lower than what was observed during earlier stages of the pandemic.

Ms. Manookian, whose group has challenged several of the federal mandates, said that the mandate “illustrates the dangers of the administrative state and how these federal agencies have become a law unto themselves.”

https://www.theepochtimes.com/us/veterans-affairs-kept-covid-19-vaccine-mandate-in-place-without-evidence-5601173?ea_src=au-frontpage&ea_med=us-news-left-3

*******************************************************

BMI, Inflammation and Cognitive Damage in Long-COVID: Findings from Vortioxetine Trial

A new study suggests that the antidepressant Vortioxetine may improve cognitive function in long COVID patients, especially those with elevated BMI. The findings underscore the interconnected impact of inflammation, metabolism, and obesity on cognitive health in post-COVID syndrome.

Up to 20% of COVID-19 cases may develop post-COVID-19 syndrome (PCC), otherwise known as long-COVID. PCC is characterized by persistent symptoms for at least two months following infection, with cognitive impairment being among the most common. This includes difficulty focusing and memory and is often described as “brain fog.”

Researchers don’t know exactly what causes cognitive impairment in PCC, but it’s suggested that disruptions in inflammation–the body’s natural defense system–may lead to immune cells attacking and damaging neural circuits. Dysfunction in metabolism, energy production, may also play a role. 

With obesity being a major risk factor in long COVID, a recent study sought to characterize the relationship between body mass index (BMI), metabolic disruption, inflammation, and cognitive impairment in long COVID patients. 

The patients were part of a randomized control trial investigating the usefulness of Vortioxetine, an antidepressant, to treat long COVID-related cognitive impairment. The research team was based at the University of Toronto, and led by Professor Roger McIntyre from the University’s Psychiatry and Pharmacology unit. 

Half of the 149 Canadian patients were treated with Vortioxetine and the other half with a placebo over the course of eight weeks. The researchers explained that “vortioxetine has immunomodulatory and antioxidative properties that are relevant to the neurobiology of PCC.” As well as cognitive symptoms, studies show vortioxetine could also help mood and physical symptoms of long COVID, including sleep problems, depression, and anxiety, though it’s not an approved treatment. 

By the end of the treatment, there was an overall improvement in cognitive function but little difference between the groups. However, if vortioxetine-treated participants had high levels of inflammation, metabolic disruption, and elevated BMI, their cognition improved more significantly than the placebo group.

“We hypothesize that individuals with these factors may positively respond to vortioxetine treatment, potentially showing a distinct treatment response profile. Larger studies with predefined variables are required to validate these hypotheses,” the authors wrote. 

The researchers also showed that those with high levels of inflammation and insulin resistance had higher levels of cognitive impairment. Insulin resistance is a defining feature of diabetes and is when cells become less responsive to the effects of insulin, leading to impaired glucose uptake and potential disruptions in metabolic health.

 “Our data are consistent with a compelling body of evidence showing that disruptions in inflammation, metabolic function and obesity hazardously affect brain health, increasing susceptibility to central nervous system and psychiatric disorders,” they wrote. 

However, they noted there were several limitations to their study. For instance, they only used one measure for inflammation,  the production of C-reactive protein (CRP) which increases in the liver as part of an inflammatory response. They wrote, “We only used one variable (e.g., TGHDL) as a proxy measure for metabolism and CRP for inflammation, which is a nonspecific marker that can be elevated for reasons unrelated to disease.”

In line with the findings, several studies show that inflammation and metabolic disruption alter nerve pathways and processes in the brain associated with cognition. For instance, one animal experiment showed that over-inflammation could inhibit neurogenesis in the hippocampus, which is essential for learning and memory. Moreover, insulin resistance and impaired energy production in nerve cells is thought to explain why those with type 2 diabetes often experience cognitive difficulties.

Based on this science, a research team from the University of Glasgow is currently investigating whether a weight loss management program could improve symptoms in long COVID patients. The research team will work closely with overweight people who are experiencing long COVID to adapt and evaluate the weight management program, which can be followed remotely from home. 

“This package of research will provide much needed hope to people with long-term health problems after COVID-19, accelerating development of new ways to diagnose and treat long COVID, as well as how to configure healthcare services to provide the absolute best care,” described Professor Nick Lemoine, Chair of NIHR’s long COVID funding committee and study contributor in a press release.

Going forward, the authors of the current study recommend that further studies should validate their findings on the interrelationship between inflammation, metabolism, BMI, and long COVID. “If confirmed, these results could open promising avenues for therapeutic interventions targeting inflammation and metabolism, aiming to alleviate symptoms and reduce the overall disease burden,” they wrote. 

They also suggested clinicians supporting long COVID patients should be cautious about and monitor the patients’ metabolic functions. 

https://www.trialsitenews.com/a/bmi-inflammation-and-cognitive-damage-in-long-covid-findings-from-vortioxetine-trial-1c470fa0

*************************************************

Also see my other blogs. Main ones below:

http://edwatch.blogspot.com (EDUCATION WATCH)

http://antigreen.blogspot.com (GREENIE WATCH)

http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH) 

http://australian-politics.blogspot.com (AUSTRALIAN POLITICS)

http://snorphty.blogspot.com (TONGUE-TIED)

https://immigwatch.blogspot.com (IMMIGRATION WATCH)

https://awesternheart.blogspot.com (THE PSYCHOLOGIST)

http://jonjayray.com/blogall.html More blogs

*********************************************************